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Abstract
Recently, the outcomes of patients with acute lymphoblastic leukemia have improved 
significantly due to the progresses achieved in diagnostics and various therapeutic inter-
ventions. In particular, the availability of several novel agents and targeted therapies 
as well as the provision of safer modalities of stem cell transplants have yielded higher 
responses and improved survival rates. The role of hematopoietic stem cell transplanta-
tion is reviewed in children and adults with acute lymphoblastic leukemia in the era of 
novel agents and targeted therapies. Various modalities of stem cell therapies in differ-
ent types of acute lymphoblastic leukemia as well as closely related issues such as graft 
versus tumor effect, minimal residual disease, and conditioning therapies are discussed 
thoroughly. In addition, various modalities of novel therapies have been discussed to be 
efficacious in clinical practice.
Keywords: acute lymphoblastic leukemia, hematopoietic stem cell transplantation, 
reduced intensity conditioning, monoclonal antibodies, immunotherapies
1. Introduction
Acute lymphoblastic leukemia (ALL) is a clonal expansion or malignant transformation and 
proliferation of lymphoid progenitor cells in the bone marrow, blood, and extramedullary 
sites [1, 2]. It is a highly heterogeneous disease comprising several entities that have distinct 
clinical manifestations, therapeutic strategies as well as prognostic implications [2]. ALL can 
occur at any age, but 80% cases occur in children [1, 3]. The incidence of ALL follows a bimodal 
distribution with the first peak occurring in children 2–5 years of age, while the second peak 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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distribution, and reproduction in any medium, provided the original work is properly cited.
is encountered around the age of 50 years [1, 3]. While most children with ALL are potentially 
curable, the prognosis in infants, adults, and elderly individuals remains poor [3].
Worldwide, different induction chemotherapeutic regimens are utilized in the treatment of 
patients with ALL [4–7]. Examples are—(1) USA and Canada: CCG series in children and 
CALGB in adults, modified DFCI 91-01 and 95-01, in addition to hyper-fractionated hyper-
CVAD (cyclophosphamide, vincristine, cytarabine, dexamethasone, methotrexate, and doxo-
rubicin); (2) UK: ALL-97, revised ALL-99 for children and UKALL XII for adults; (3) France: 
FRALLE-93 in children, LALA-94 in adults and GRAALL-2003; (4) Germany: pediatric DCOG-
ALL or Berlin-Frankfurt-Munster [standard or augmented regimen]; (5) Italy: AIEPO [pedi-
atric] and GIMEMA [adults]; (6) Holland and Belgium: HOVON-70; (7) Spain: PETHEMA 
ALL-96; (8) Sweden and Finland: pediatric NOPHO-92 and adult Nordic protocols; and (9) 
Mexico: LALIN (pediatric) and LALA (adult) [4–7]. Sometimes, different chemotherapeu-
tic regimens are used in the same geographic location or even in the same country [4–7]. 
Additionally, these treatment regimens undergo modifications or even total replacement 
once new literature data or results of large studies become available [4–8]. Despite the devel-
opment of several induction regimens, there is no single best regimen for induction therapy in 
ALL [4–8]. The main constituents of these chemotherapeutic regimens are almost similar with 
different dosing and treatment schedules and they include: daunorubicin, doxorubicin, or 
idarubicin; prednisolone or dexamethasone; vincristine; L-asparaginase; cyclophosphamide; 
6-mercaptopurine; and intrathecal (IT) as well as intravenous (IV) methotrexate [4–8].
Recently, the more intensified pediatric ALL induction regimens have been used in adoles-
cents and young adults (AYAs), 15–40 years of age, having ALL, and their use has been associ-
ated with superior response rates [4, 6, 9]. Several studies have shown that AYAs treated with 
adult chemotherapeutic regimens have poorer outcome compared with patients belonging 
to the same age group treated with pediatric-inspired regimens [4, 6, 9]. Additionally, cer-
tain cancer centers, such as Dana-Farber Cancer Center, USA, are currently treating patients 
between the ages of 1 and 50 years with the same regimens of chemotherapy [5]. The recent 
incorporation of novel and targeted therapies, such as tyrosine kinase inhibitors (TKIs), nelar-
abine and rituximab, into the induction therapy of ALL has further improved the response 
rates and the outcomes in general [4, 5, 10–12].
2. HSCT in ALL patients
2.1. GVL effect in ALL
Several studies have shown that (1) in adults with ALL receiving cytotoxic chemotherapy, the 
high incidence of relapse is the main cause of treatment failure, hence post-remission therapy 
particularly the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) is a crit-
ical issue; (2) the rates of relapse of ALL following HSCT are higher than those encountered 
in other hematologic malignancies; (3) relapse of ALL post-allogeneic HSCT is a major cause 
of treatment failure as it is associated with an extremely poor prognosis; (4) graft versus host 
disease (GVHD) encountered in the post-HSCT period has a protective effect against disease 
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relapse; and (5) graft versus leukemia (GVL) effect plays a major role in curing patients with 
ALL subjected to allogeneic HSCT [13–17]. However, there is considerable evidence for the 
existence of GVL effect after HSCT in patients with ALL: (1) relapse rates are lower in recipi-
ents of allogeneic HSCT compared with recipients of autologous grafts, (2) relapse rates are 
lower in patients who develop acute or chronic GVHD following allografts, and (3) the use 
of interferon immediately post-allogeneic HSCT may reduce relapse rate through stimula-
tion of an immunological response [15, 18]. Unfortunately, the efficacy of GVL effect in the 
context of donor lymphocyte infusion (DLI) of ALL in the post-allogeneic HSCT setting is 
quite unimpressive as response rates to DLI in ALL patients receiving allografts have been 
reported to range from 0 to 18% [15, 18].
GVL effect in ALL is influenced by the extent of leukemia burden [15]. Minimal residual dis-
ease (MRD) studies after HSCT have found a strong correlation between the presence of MRD 
and relapse of leukemia [16]. Frequent MRD monitoring post-allogeneic HSCT may predict 
ALL relapse early enough, thus allowing the implementation of various approaches such as: 
(1) reduction of immunosuppressive therapy, (2) DLI, and (3) adoptive T-cell therapy, but 
such approaches may be ineffective in the presence of high disease burden [15, 16].
The development of GVHD following allogeneic HSCT in patients with B-cell ALL is asso-
ciated with a lower probability of leukemia relapse due to a non-specific inhibition of 
B-lymphocytosis [19]. Also, the improved survival in recipients of allogeneic HSCT who 
develop acute or chronic GVHD is attributed to the beneficial GVL effect of GVHD [14]. 
Chronic GVHD, particularly limited form, is associated with a significant GVL effect [13]. 
However, the correlation between GVHD and GVL is mainly seen in non-T cell-depleted 
allografts [14]. The influence of chronic GVHD on the risk of relapse has been found to be 
prominent in patients with chromosomal translocations or normal cytogenetics [13].
Studies have shown that in ALL patients subjected to allogeneic HSCT, relapse rates are 
higher in: (1) patients receiving dual or effective GVHD prophylaxis as the intensity of the 
GVHD prophylactic regimen inversely correlates with the incidence of acute GVHD and (2) 
recipients of matched sibling donor (MSD) allografts compared with those receiving matched 
unrelated donor (MUD) grafts as MSD allogeneic HSCT is associated with reduced likelihood 
of GVHD and reduced treatment-related mortality (TRM), while MUD allografts are associ-
ated with higher incidence of GVHD and lower relapse rates due to the pronounced GVL 
effect of GVHD [14, 17, 20].
In ALL patients receiving allogeneic HSCT, GVL effects are associated with detectable Wilms 
tumor-1-specific T lymphocyte (WT1) [18]. These results support the immunogenicity of WT1 
after HSCT for ALL and highlight the potential for WT1 vaccines to boost GVL effect after 
HSCT for ALL [18]. The lower relapse rates encountered in ALL patients receiving HSCT may 
indicate that viral antigens play a role in the induction of anti-leukemic effect [14].
2.2. MRD in ALL
Several studies have shown the prognostic relevance of detection of MRD in patients with 
ALL [21–23]. MRD identified prior to allogeneic HSCT is the strongest predictor of post-HSCT 
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relapse in ALL patients [23]. Thus, elimination of pre-HSCT MRD in patients with ALL by 
novel therapeutic approaches or drug combinations may decrease the risk of post-HSCT 
relapse and improve overall survival (OS) [23].
MRD evaluation or monitoring in ALL patients can be performed by: (1) flow cytometry, 
(2) real-time quantitative polymerase chain reaction (RT-Q-PCR), and (3) next-generation 
sequencing (NGS) [21, 22]. Currently, analysis of MRD is mostly performed by PCR analysis 
of immunoglobulin (IG) and T-cell receptor (TCR) gene rearrangements, and this method has 
sensitivity of 10−4 in patients with ALL [21, 24]. However, despite the broad clinical usefulness 
of MRD evaluation, false-positive MRD results can be obtained due to massive B-lymphocyte 
regeneration after HSCT [24].
NGS enables precise and sensitive detection of multiple antigen receptor rearrangements, 
thus providing more specific readout compared to RT-Q-PCR, and this will reflect positively 
on the treatment interventions in ALL patients undergoing HSCT [24]. MRD determines the 
outcome of autologous HSCT in patients with HR-ALL [25]. In patients with ALL planned for 
autologous HSCT, MRD evaluation by PCR or NGS may play a role in the direction of therapy 
as it can predict long-term relapse-free survival [26, 27]. For example, patients with SR-ALL 
who do not have HR features at diagnosis and who have pre-transplantation negative MRD 
can be offered autologous HSCT combined with maintenance therapy [26].
2.3. Autologous HSCT in ALL
Complete remission (CR) can be achieved in approximately 80% of adults with ALL, but 
relapse occurs frequently leading to poor long-term disease-free survival that ranges between 
25 and 40% [28, 29]. The post-remission therapies for patients with ALL generally include: 
(1) consolidation followed by maintenance chemotherapy, (2) allogeneic HSCT for high-risk 
(HR) patients, and (3) autologous HSCT for standard-risk (SR) patients or HR patients who do 
not have an HLA identical sibling donor [26, 29]. Therefore, after achieving first CR, intensive 
therapies, such as allogeneic HSCT and autologous HSCT, are generally offered to patients 
who are eligible for HSCT [28].
Autologous HSCT was first introduced as a treatment for ALL patients nearly 60 years ago 
[29]. However, autologous HSCT has been underutilized in ALL patients [29, 30]. Autologous 
HSCT performed in patients with ALL in CR1 has produced leukemia-free survival rang-
ing between 45 and 65% [29]. Strategies to enhance autologous GVL effect after HSCT may 
enhance long-term survival in ALL patients subjected to autologous HSCT [31].
In patients with ALL, factors identifying patients who are at high risk of relapse include: (1) age 
more than 35 years, (2) T-cell type of ALL, (3) elevated white blood cell (WBC) count at presenta-
tion, (4) elevated serum lactic dehydrogenase (LDH) level at diagnosis, (5) extramedullary dis-
ease (EMD) prior to HSCT, (6) specific cytogenetic abnormalities, (7) blast cell proportion ≥5% 
on day 15 of induction therapy, and (8) having MRD at various stages during therapy [26, 27]. 
These factors indicate poor prognosis and decreased OS as well as disease-free survival (DFS) 
[26, 27]. Factors such as the risk features at the time of diagnosis and MRD following induction 
therapy greatly affect the outcome of autologous HSCT in ALL patients [29]. SR patients with 
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ALL who lack poor prognostic factors will benefit from autologous HSCT. Also, HR patients 
with ALL who are likely to benefit from autologous HSCT include: (1) rapid responders who 
achieve CR after the first induction therapy and (2) those with negative pre-HSCT MRD [25, 
26, 28, 29]. In ALL patients, autologous HSCT should be performed after completion of con-
solidation chemotherapy as an alternative to maintenance chemotherapy [25]. Autologous 
HSCT combined with post-transplantation maintenance therapy could be a valid therapeutic 
option in adult patients with ALL [26, 30]. Adoptive immunotherapy and maintenance ther-
apy after autologous HSCT reduce relapse rate and improve outcome in patients with ALL 
[30, 32]. Post-autologous HSCT maintenance therapy can be in the form of: (1) 6-mercapto-
purine, methotrexate, vincristine, and prednisolone or (2) TKIs in patients with Philadelphia 
chromosome-positive (Ph+) ALL [27, 30]. Novel therapies, such as blinatumomab, may reduce 
the burden of MRD before stem cell collection prior to autologous HSCT, thus making the 
combination of novel therapies and autologous HSCT a real alternative to allogeneic HSCT and 
prolonged maintenance therapy for ALL patients [27]. Improved DFS and low relapse rates 
can be achieved after autologous HSCT in adults with ALL who (1) rapidly respond to the first 
induction chemotherapy and (2) achieve MRD prior to autologous HSCT [26, 28]. Long-term 
outcome of allogeneic HSCT is superior to autologous HSCT or maintenance chemotherapy 
[27–29]. Several studies have failed to demonstrate the superiority of autologous HSCT over 
chemotherapy in adult patients with ALL [27–29]. Before the era of novel therapies and hap-
loidentical HSCT, the prognosis of patients with ALL who relapse post-autologous HSCT was 
reported to be dismal due to the few available therapeutic options [29].
2.4. Allogeneic HSCT conditioning therapies
Allogeneic HSCT cures hematologic malignancies through two major mechanisms: (1) pre-
transplantation conditioning therapy that kills leukemic cells directly and (2) graft versus 
tumor (GVT) effect [33]. Over the past 25–30 years, the outcome of HSCT has been steadily 
improving due to improvements in: (1) conditioning therapies, (2) GVHD prophylaxis and 
therapy, (3) supportive care facilities, (4) new antifungal agents, (5) better diagnostic tools, 
(6) incorporation of novel and targeted therapies such as TKIs into conventional therapeutic 
regimens, and (7) donor selection by improvement of human leukocyte antigen (HLA) typing 
methods and the increased use of MUDs [13, 34, 35]. Also, the use of flow cytometry and PCR 
for evaluation of MRD and monitoring of early relapse has improved the outcome of HSCT 
further [34]. Pre-transplantation detection of MRD by flow cytometry or PCR has been associ-
ated with lower OS and relapse-free survival [34].
For the past 40 years, the standard myeloablative conditioning (MAC) regimen for ALL is 
composed of total body irradiation (TBI) 1200 cGy and IV cyclophosphamide 120 mg/Kg 
body weight [36, 37]. In patients with ALL, relapse is common after HSCT [37]. Attempts to 
decrease the risk of relapse following HSCT include: (1) modulation of the conditioning regi-
men by increasing TBI dose to >1200 cGy or adding a second chemotherapeutic agents such as 
etoposide and (2) decreasing the intensity of the conditioning regimen by relying on immune 
modulation, GVL effect, for disease control [36]. However, the optimal conditioning therapy 
for transplant-eligible patients with ALL has not been defined yet [38].
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The MAC regimens for ALL consist of: TBI (1200–1400 cGy) in addition to one or more che-
motherapeutic agents [36]. In children with ALL, the MAC therapies include: (1) TBI 1000–
1200 cGy + cyclophosphamide, (2) TBI 1000–1200 cGy + cyclophosphamide + etoposide, (3) 
TBI 1320–1400 cGy + cyclophosphamide, and (4) TBI 1320–1400 cGy + cyclophosphamide + 
etoposide [36]. Studies have shown that (1) etoposide + fractionated TBI and cyclophospha-
mide + fractionated TBI are equally effective, (2) effectiveness of chemotherapy alone, such as 
IV busulfan + melphalan, conditioning therapy in patients with HR ALL, (3) there is an advan-
tage of substituting etoposide for cyclophosphamide or increasing the TBI dose to ≥13 Gy 
when cyclophosphamide is used, and (4) treosulfan, etoposide, and cyclophosphamide con-
ditioning regimen has favorable toxicity profile with lower NRM [33, 35, 39, 40].
In comparison to TBI-containing conditioning regimens, fludarabine and pharmacokinetic-
targeted busulfan conditioning therapy appears to be safer and equally effective in control-
ling ALL [41]. Fludarabine + amsacrine + cytarabine (FLAMSA) + anti-thymocyte globulin 
(ATG) + fractionated TBI conditioning regimen followed by allogeneic HSCT is feasible and 
effective in patients with HR or relapsed ALL, thus presenting a potential alternative to the 
classical TBI and cyclophosphamide MAC therapy [37]. Studies have shown that (1) combina-
tion of busulfan and clofarabine provides an effective control while maintaining a favorable 
safety profile and has produced OS and NRM rates comparable to those achieved with tradi-
tional TBI-based conditioning regimens and (2) busulfan + fludarabine + ATG + TBI condition-
ing therapy has achieved excellent outcomes in all patients with ALL except older patients 
with comorbidities [38, 42, 43].
The incorporation of etoposide into the intensified conditioning regimens has been associ-
ated with improved disease control but at the expense of higher rates of toxicity and TRM 
[37]. Medium-dose etoposide, cyclophosphamide, and TBI conditioning therapy is suitable 
for adults with HR-ALL in CR1 and SR-ALL in CR2, below the age of 50 years, as it has 
been shown to be associated with: lower relapse rate, no increase in toxicity, and better OS 
[44, 45]. In children and adolescents with ALL, the addition of etoposide to TBI + cyclo-
phosphamide conditioning regimen should be avoided due to increased risk of mortality. 
Also, TBI dose >1300 cGy should be avoided due to increased risk of second malignancy 
[36]. In children with ALL in CR1 and CR2, the incorporation of alemtuzumab, anti-CD52 
monoclonal antibody, into the MAC therapy in MUD allografts has produced durable 
engraftment with low rates of GVHD and comparable rates of DFS to recipients of MSD 
transplants [46]. Thiotepa-based conditioning regimen for allogeneic HSCT in patients 
with ALL is feasible and effective, and it has produced main outcomes comparable to those 
achieved by other conditioning therapies [47]. In children with ALL transplanted in second 
CR, the 3-year DFS using MAC followed by allogeneic HSCT has been reported to range 
between 30% and 70% [48].
Reduced intensity conditioning (RIC) regimens have been used extensively in adults with 
hematologic malignancies including ALL [48]. In MAC regimens, relapse protection is pro-
vided by dose-intensive chemotherapy ± TBI, while in RIC regimens, relapse protection is 
provided by GVL effect [44, 48]. The indications for RIC-allogeneic HSCT include: (1) old 
age, (2) poor performance status, (3) active infection, (4) significant organ dysfunction, and 
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(5) presence of comorbid medical conditions [44, 48]. Compared with MAC regimens, RIC 
regimens have been associated with acceptable rates of donor engraftment and lower rates 
of TRM [48]. In children with ALL, the use of RIC regimens has achieved long-term DFS, but 
it has been associated with high rates of TRM, acute and chronic GVHD, myelosuppression, 
and disease relapse [44, 48]. In adult patients with HR-ALL receiving umbilical cord blood 
transplantation (UCBT): (1) MAC regimens have been associated with DFS comparable to 
that reported with other stem cell sources and (2) the results of RIC regimens are encouraging 
[49]. New therapeutic strategies for adults with ALL are increasingly utilized with better out-
comes and they include: (1) various TKIs for Ph+ ALL, (2) pediatric inspired chemotherapeu-
tic regimens for Philadelphia chromosome-negative (Ph−) ALL, and (3) HLA-haploidentical 
HSCT [44]. However, the optimal therapeutic modality should be selected after taking the 
following factors into consideration: age of the patient, Philadelphia chromosome positivity, 
donor availability, disease risk stratification, and efficacy as well as safety of the therapeutic 
measure [44].
2.5. Allogeneic HSCT in ALL
Cytogenetic abnormalities occur in 60–85% of patients with ALL. However, numerical chro-
mosomal abnormalities, alone or in association with structural changes, occur in 50% of ALL 
patients [2, 50, 51]. The most common chromosomal abnormalities that are encountered in 
patients with ALL are listed in Table 1 [2, 50, 51]. In patients with ALL, certain HR features 
predict poor long-term outcome even in patients receiving intensive chemotherapy. These 
HR features are shown in Table 2 [2, 3, 50, 52–55]. Patients having HR features, including 
HR cytogenetic abnormalities and genetic mutations, are less likely to respond well to che-
motherapy and are more likely to relapse. Hence, this category of patients may require not 
only more intensified chemotherapeutic regimens but also novel therapies as well as HSCT 
in order to have optimal control of their leukemia [2, 3, 50, 52–55]. The main indications of 
allogeneic HSCT in children and adults with ALL are shown in Table 3 [7, 23, 51–54, 56–65].
In adults with ALL, post-remission therapies include: consolidation chemotherapy followed 
by maintenance therapy, autologous HSCT, and allogeneic HSCT [66, 67]. There is controversy 
regarding the role of frontline allogeneic HSCT for patients with ALL in CR1 [68]. However, 
three meta-analyses showed potential benefit of allogeneic HSCT in CR1 [67–69]. These three 
meta-analyses included 41 studies and they came to the following conclusions: (1) myeloabla-
tive MSD allografts had absolute survival benefit of 10–15% at 5 years compared to chemo-
therapy alone or chemotherapy followed by autologous HSCT, (2) MSD allografts improve 
survival in patients younger than 35 years and are the optimal post-remission therapy in ALL 
patients ≥15 years old, (3) no beneficial effect of autologous HSCT in comparison to chemo-
therapy, and (4) MSD allografts offer superior OS as well as DFS and significantly reduce 
the risk of relapse but carry increased risk of NRM [67–69]. For patients with relapsed and 
refractory ALL, allogeneic HSCT is the only potentially curative therapeutic modality [68]. 
Three major studies that included 1419 patients with relapsed ALL in adults showed that 
the prognosis of relapsed ALL in adults was very poor and that the 5-year OS of adults with 
relapsed ALL not subjected to allogeneic HSCT ranged between 0.0 and 10% [70–72].
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Either MAC therapies or RIC regimens can be offered according to the age and comorbid 
medical conditions of the HSCT recipient [73, 74]. In patients with acute leukemia, the follow-
ing stem cell sources have been utilized in allogeneic HSCT: MSD, MUD, and UCB [73, 75].
2.6. Focus on haploidentical HSCT
Haploidentical HSCT evolved several decades ago, and it has undergone several modifica-
tions and remarkable developments in relation to: conditioning therapy, post-transplantation 
immunosuppression, and graft manipulation [73, 76]. Historically, the main obstacles to suc-
cessful haploidentical HSCT were graft failure, intractable GVHD, decreased GVL effect, 
and delayed immune reconstitution [75, 76]. This form of HSCT is readily available for the 
majority of patients with acute leukemia and is an acceptable alternative to other donor 
sources of stem cells [75–77]. Techniques that are used to improve the outcome of haploiden-
tical HSCT include: (1) CD3/CD19 depletion to reduce GVHD, (2) KIR B haplotype donors 
1. Philadelphia chromosome [t9,22]: The commonest cytogenetic abnormality. Encountered in 15–30% of adults and 
5% of children with ALL
2. Chromosomal abnormalities that are associated with higher risk of central nervous system involvement:
• t4,11
• t8,14
• t14q+
3. Chromosomal abnormalities that are associated with:
• High white cell and blast cell counts at presentation
• High risk of relapse
• t9,22
• t4,11
4. Other common cytogenetic encountered in patients with ALL:
• t10,14
• t1,14
• Deletion 11q22
• Deletion 11q23 [MLL]
• Hypodiploidy
• Hyperdiploidy
ALL, acute lymphoblastic leukemia and MLL, mixed lineage leukemia.
Table 1. The most common chromosomal abnormalities in patients with ALL.
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1. Age: <1 year and >35 years
2. White blood cell count at presentation:
• > 30,000 in B-lineage
• > 100,000 in T-lineage
3. Cell type: pro-B; early and mature T
4. Immunophenotyping:
• CD 20 positivity
• CD 10 negative pre-B ALL.
5. Poor performance status: >1
6. Poor response to prednisolone
7. Peripheral blood blasts ≥5% on day: 8–15
8. Failure to achieve remission >4 weeks of induction chemotherapy
9. Involvement of central nervous system
10. Clinical relapse: >First complete remission
11.  Minimal residual disease: Detectable molecular and immunophenotypic evidence of disease while in morpho-
logic remission.
12. High-risk cytogenetic and molecular abnormalities:
• +8
• −7
• Deletion 6q
• Low hypodiploidy
• Near triploidy
• Immunoglobulin H gene rearrangement
• Intrachromosomal amplification of chromosome 21
• Translocation 8,14
• Translocation 4,11
• Translocation 1,19
• Translocation 9,22
• Philadelphia-like
• Complex cytogenetics
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confer rapid natural killer cell proliferation soon after HSCT resulting in lower relapse rates 
due to GVL effect, and (3) infusion of high numbers of CD34+ cells to improve immune 
reconstitution [77].
Historically, mega doses of stem cells had been used after T-cell depletion in order to avoid 
development of GVHD, but this maneuver had been associated with high incidence of graft 
failure and disease relapse [73, 78]. Recently, unmanipulated allografts and post-transplanta-
tion cyclophosphamide have been used with high success [73, 74, 78]. Also, it has been shown 
that the outcome of unmanipulated haploidentical HSCT in adult patients with acute leuke-
mia are comparable to those of unrelated UCBT and MUD allografts [74, 78].
Adults Children
1. Philadelphia chromosome-positive ALL in CR1
2. ALL with Philadelphia-like molecular signature
3. High-risk or very high-risk ALL in CR1
4. Relapsed ALL [ALL in CR2 or beyond]
5.  Primary refractory disease [ALL refractory to induction or first-line 
chemotherapy]; once CR is achieved following salvage therapy, al-
logeneic HSCT can be performed
6.  Presence of MRD at any stage during the course of the disease, re-
gardless their initial risk group [standard risk or high risk]
7. MLL [mixed lineage leukemia] gene rearrangement
1. Severe hypodiploidy
2. Persistent MRD
3. T-cell ALL with poor response to prednisolone
4. Primary induction failure
5. MLL gene rearrangement in infants with ALL
6.  Relapsed ALL [ALL in CR2]: bone marrow or 
extramedullary relapse
ALL, acute lymphoblastic leukemia; CR, complete remission; MLL, mixed lineage leukemia; and MRD, minimal residual 
disease.
Table 3. Indications of allogeneic HSCT in patients with ALL.
13. High-risk genetic mutations:
• IKZF1 deletion [IKAROS]
• Unmutated NOTCH1
• MLL [mixed lineage leukemia] gene rearrangement: 11q23
• RAS-PTEN altered
• JAK 2 mutation
• KMT2A rearrangement
• CREBBP
• CRLF2
• ETP
• PBX-E2A+
• BAALC+
Table 2. High-risk features that predict poor long-term outcome even with intensive chemotherapy in patients with 
acute lymphoblastic leukemia.
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In patients with Ph− ALL in CR1, studies have shown that (1) outcomes of haploidentical 
HSCT are comparable to MSD and MUD allografts and (2) outcomes of HR patients are 
comparable to those of low-risk patients once haploidentical allografts are used. Therefore, 
haploidentical HSCT represents a valuable alternative for patients with Ph− ALL lacking 
MSDs [79, 80]. In adult patients with HR-ALL in CR1, haploidentical HSCT performed with 
post-transplantation cyclophosphamide-based GVHD prophylaxis has produced 52% DFS at 
3 years, thus providing a suitable alternative to HLA-matched transplantation [68].
Also in adults with HR-ALL in CR1 and CR2 or beyond, unmanipulated haploidentical trans-
plants have been associated with 3-year OS and DFS of 33 and 31%, respectively; thus, unma-
nipulated haploidentical allografts can be considered a valid option for adults with HR-ALL 
lacking HLA-identical donors particularly if performed in early disease status [74]. Compared 
to HLA-matched related donor allografts, haploidentical HSCT has produced similar rates of 
long-term survival and NRM but lower relapse rates in patients with Ph+ ALL, thus haploi-
dentical HSCT represents a valid therapeutic option for patients who lack a suitable HLA-
matched donor [81, 82].
2.7. HSCT in T-cell ALL
T-cell ALL is an aggressive neoplasm derived from malignant transformation of lympho-
blasts committed to T-cell lineage [83]. It accounts for 10–25% of all cases of ALL [84–86]. 
Given the rarity of T-cell ALL, patients are typically treated in a similar fashion to B-cell 
ALL with pediatric inspired dose-intense multi-agent chemotherapy regimens in addition to 
central nervous system (CNS) prophylaxis [83–85]. T-cell ALL carries a poor prognosis com-
pared with B-cell ALL due to: (1) higher relapse rates even if they respond to chemotherapy 
and achieve CR and (2) more extensive involvement of bone marrow and extramedullary 
sites, particularly the mediastinum [83, 84, 86]. Even with the current intensive chemothera-
peutic regimens, the 5-year event-free survival (EFS) is 80%, whereas the 10-year EFS is only 
15% [84].
Allogeneic HSCT is a potentially curative therapeutic option for patients with T-cell ALL, 
but relapse after allogeneic HSCT is a major cause of treatment failure [86]. Patients with 
T-cell ALL who lack an HLA-matching donor for allogeneic HSCT should preferably have 
prolonged maintenance chemotherapy [83]. Studies have shown that (1) in children with 
T-cell ALL in CR2 subjected to allogeneic HSCT, the 3-year OS is about 50% and (2) in 
adults with T-cell ALL including the aggressive early-thymic precursor (ETP) subtype sub-
jected to allogeneic HSCT in CR1, the 3-year OS is 62% and those transplanted in CR2 or 
beyond, the 3-year OS is 24% indicating the better outcome of allogeneic HSCT in CR1 in 
adults [84, 85]. Other studies on adults with T-cell ALL subjected to allogeneic HSCT have 
shown the following results: (1) allogeneic HSCT is safe and effective in overcoming the 
poor prognosis particularly when applied early, (2) there was controversy regarding the 
use of TBI in the conditioning therapies as some studies highlighted the importance of 
having TBI as part of the conditioning regimen, while other studies showed no differ-
ence between TBI-based and busulfan-based conditioning therapies, and (3) MRD status 
at transplantation is highly predictive of disease relapse, suggesting that novel therapies 
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can be offered before and after allogeneic HSCT to improve the outcome of this group 
of patients [85–88]. Patients with refractory T-cell ALL can be treated successfully with 
unmanipulated allografts from HLA-mismatched haploidentical siblings as haploidentical 
HSCT offers higher GVL effect [89, 90].
Nelarabine, a prodrug of Ara-G, has shown selective cytotoxicity against T-cell lympho-
blasts and is usually used in relapsed and refractory T-cell ALL [83, 91]. Nelarabine is a 
valuable therapeutic option in patients with T-cell ALL relapsing after allogeneic HSCT as 
it has shown response rates reaching 81%; hence it should be considered in: (1) treating 
relapses post-allogeneic HSCT and (2) maintenance therapy following transplantation in 
HR patients [91].
Gamma delta subtype of precursor T-cell ALL is usually treated with the same intensive che-
motherapeutic regimens like other types of ALL (T- and B-cell types) [92]. In this rare type of 
T-cell ALL, the preferred therapy is usually induction chemotherapy to achieve CR followed 
by upfront allogeneic HSCT to eradicate the potential residual disease by the GVT effect of 
allogeneic HSCT [92].
2.8. HSCT in Ph+ ALL
Philadelphia chromosome positivity is the most common recurrent cytogenetic abnormality 
observed in adult patients with ALL [93–95]. Approximately 20–25% of adults and only about 
2% of children with ALL harbor Philadelphia chromosome and express the bcr-abl transcript 
[93, 96, 97]. In recent years, the most significant therapeutic advancement has been the intro-
duction of TKIs into the therapeutic regimens of Ph+ ALL [94]. In the era before TKIs, patients 
with Ph+ ALL were having poor prognosis after standard chemotherapy with DFS rates rang-
ing between 0.0% and 20% [94, 96]. Historically, adult Ph+ ALL had been associated with high 
relapse rates and short DFS and OS [98].
Results of autologous HSCT in adults with Ph+ ALL are still disappointing [99]. Studies 
have shown that (1) Ph+ ALL is incurable without allogeneic HSCT and (2) in patients with 
Ph+ ALL, particularly adults, who are eligible for HSCT and who have achieved CR alloge-
neic HSCT, has remained the consolidation therapy of choice and the only proven curative 
therapeutic strategy [94, 96, 98–101]. However, patients with Ph+ ALL planned for allogeneic 
HSCT can be divided into three risk groups or categories: (1) HR; positive MRD or overt clini-
cal disease, (2) intermediate risk; molecular disease but without morphologic disease, and (3) 
low risk; no evidence of MRD [96].
In children and adolescents with Ph+ ALL, allogeneic HSCT is a controversial issue and there 
is increasing reluctance to offer allogeneic HSCT to children in the era of TKIs [94, 97, 102]. 
The children’s Oncology Group reported the following results on the use of TKIs in chil-
dren and adolescents with Ph+ ALL: (1) excellent outcomes of the combination of TKI and 
chemotherapy with OS of 88% at 3 years and 70% at 5 years, (2) achievement of complete 
hematological remission in approximately 95% of cases and molecular remission in >50% of 
patients, and (3) no advantage of subjecting patients to allogeneic HSCT [103, 104]. On the 
contrary, in children and young adults with Ph+ ALL, studies have shown that (1) results 
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of allogeneic HSCT are superior to chemotherapy alone, (2) MSD and MUD allografts have 
yielded equivalent outcomes, (3) in patients subjected to allogeneic HSCT, age, WBC count 
at presentation, and early response to treatment have been shown to be independent prog-
nostic indicators, (4) early allogeneic HSCT is recommended once morphologic remission is 
achieved as this form of treatment has shown to produce durable remissions in patients with 
CR1, and (5) in children with Ph+ ALL, two studies showed advantage of allogeneic HSCT in 
protection against late disease relapses and in achieving 5-year OS and DFS of 80.2 and 72.9%, 
respectively [105–108].
In patients with Ph+ ALL, achievement of complete molecular remission (CMR) prior to 
allogeneic HSCT reduces the risk of leukemia relapse post-allogeneic HSCT even though 
TKIs may still rescue some patients who relapse after transplantation [109, 110]. Without 
TKIs, 30–50% of patients with Ph+ ALL relapse after allogeneic HSCT [96]. Even in the era 
of TKIs, relapse is still the main cause of allogeneic HSCT failure in HR patients Ph+ ALL 
[111]. Ph+ ALL patients, subjected to allogeneic HSCT, should ideally be (1) in CR and with-
out MRD prior to transplantation and (2) below 60 years of age. However, only carefully 
selected patients ≥60 years old are candidates for allogeneic HSCT [100, 112]. In patients 
with Ph+ ALL, RIC allogeneic HSCT can be offered to older patients and those with comor-
bidities, that is, patients who are ineligible for MAC therapy [100, 112].
Additional cytogenetic abnormalities, such as monosomy 7, and abnormalities of chromo-
somes 8 and 9 are common in patients with Ph+ ALL as they are encountered in two thirds of 
cases [113]. Pre-existing mutations in the ABL kinase domain are frequently associated with 
resistance to TKIs and are a common cause of post-HSCT relapse in patients with Ph+ ALL 
[101]. Pre-transplantation risk factors for relapse in patients with Ph+ ALL include: (1) expres-
sion of P190 transcript, (2) evidence of morphologic disease at the time of transplantation, 
and (3) type of donor, with recipients of autologous HSCT or MSD having the highest risk of 
relapse [96]. Post-transplantation risk factors for relapse in patients with Ph+ ALL include: (1) 
expression of P190 transcript which carries the highest risk of relapse, (2) detection of MRD 
by reverse transcription PCR for bcr-abl transcript, and (3) lack of chronic extensive GVHD 
[96]. These risk factors can be utilized to improve risk stratification for patients with Ph+ ALL 
undergoing HSCT in order to develop specific strategies or therapeutic plans [96]. In patients 
with Ph+ ALL subjected to allogeneic HSCT, TKI therapy tailored according to pre-transplan-
tation TKI response, anticipated toxicities, and Abl-1 domain mutations is feasible and may 
reduce relapse rate and improve the outcome of patients [111].
2.9. Relapse of ALL before and after HSCT
Approximately 20–25% of ALL patients experience relapses of their disease at 5 years from 
diagnosis and initial therapy despite receiving the standard chemotherapeutic regimens [114, 
115]. The prognosis of children and young adults with relapsed ALL is poor [114, 115]. Only a 
minority of adults with ALL who relapse after first line therapy can be rescued [116]. Salvage 
chemotherapy in patients with relapsed ALL includes: (1) mitoxantrone, etoposide, and 
cytarabine or (2) fludarabine, cytarabine, pegylated-asparaginase, and granulocyte colony 
stimulating factor [116]. Salvage chemotherapy alone is not curative in relapsed ALL [115]. 
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Allogeneic HSCT offers the best and may be the only chance for cure in relapsed ALL, par-
ticularly in adult patients [114–116]. Allogeneic HSCT can be performed using either a sibling 
donor or an unrelated donor [114, 115].
In patients with ALL, relapse after HSCT remains the main cause of treatment failure due to 
the limited therapeutic options and the associated poor outcome [117–119]. Factors that affect 
the occurrence as well as the outcome of ALL relapse after HSCT include: GVHD, MRD, 
intrinsic factors of the disease, and transplantation characteristics [120]. The prognosis of 
patients with ALL who relapse after HSCT is extremely poor with long-term survival <10%, 
and there is no difference in short-term survival between patients with isolated EMR and sys-
temic relapse, suggesting that all disease relapses should be treated systemically [118]. EMR 
after allogeneic HSCT poses significant challenge for transplantation physicians as it carries 
poor outcome and has limited therapeutic options [119]. The risk factors for EMR, particularly 
CNS relapse, after allogeneic HSCT include: HR cytogenetics, advanced disease status, male 
gender, history of EMD before HSCT, hyperleukocytosis at diagnosis, and receiving periph-
eral blood stem cells [119]. However, prophylactic IT chemotherapy and maintenance treat-
ment after HSCT may reduce the rate of CNS relapse post-HSCT [119].
Treatment of ALL relapse post-HSCT includes: (1) continuation of low-dose immunosuppres-
sive therapy may be the optimal approach as abrupt discontinuation of immune suppression 
does not lead to any clinical benefit and may result in aggravation of GVHD, (2) re-induction 
or salvage therapy followed by second allogeneic HSCT in highly selected patients may offer 
the best chance of prolonged survival, and (3) other interventions, such as frequent MRD 
monitoring, pre-emptive immunotherapy in the form of DLI, post-transplantation mainte-
nance therapy, use of novel and targeted therapies in post-HSCT, and enrollment in clinical 
trials [117, 118, 120].
Prerequisites for successful management of ALL post-HSCT relapse by either second allo-
geneic HSCT or experimental non-transplant approaches include: good clinical condition of 
the patient and the capacity to achieve hematological remission by the salvage therapy [117]. 
For patients with acute leukemia who relapse after the first allogeneic HSCT, only a second 
allograft can provide a realistic chance of long-term disease remission [121]. The second allo-
geneic HSCT used in the treatment of relapse after the first allograft can be obtained from 
HLA-MSD, MUD, or HLA-mismatched alternative donor [122]. Based on the rapid donor 
availability as compared to MUD, a haploidentical second allogeneic HSCT might be consid-
ered as an alternative therapeutic option for relapse after the first allograft [122, 123].
3. Novel and targeted therapies in ALL
3.1. Tyrosine kinase inhibitors
The introduction of TKIs has revolutionized the therapy of patients with Ph+ ALL [94, 107]. 
Over the past 12 years, administration of TKIs before allogeneic HSCT has significantly 
improved the long-term outcome of allogeneic HSCT in adults with Ph+ ALL [93, 107]. In 
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patients with Ph+ ALL, TKIs have been incorporated into: (1) the induction phase in conjunc-
tion with cytotoxic chemotherapy, (2) in the consolidation and maintenance phases in con-
junction with cytotoxic chemotherapy in patients who are not eligible for allogeneic HSCT, 
and (3) in the post-transplantation maintenance therapy in recipients of allogeneic HSCT and 
their incorporation into the treatment regimens at various stages of the disease has signifi-
cantly improved the outcomes of patients [10–12, 93, 124].
3.1.1. Imatinib
Studies in children with Ph+ ALL have shown that (1) the incorporation of imatinib into the 
chemotherapeutic regimens has improved the prognosis and (2) TKIs administered in the 
early phases of therapy can dramatically reduce MRD and improve the outcome of patients 
[12, 94, 124, 125]. Also, several groups have reported that the combination of imatinib and 
high dose chemotherapy has significantly improved the outcome of children and adults with 
Ph+ ALL with CR rates reaching 86–95% and 1-year OS reaching 75% [94, 124]. The 4-year OS 
in Ph+ ALL subjected to allogeneic HSCT in the era of imatinib has increased significantly to 
reach 52% [94]. Imatinib maintenance following allogeneic HSCT may further improve the 
outcome of patients with Ph+ ALL [125].
3.1.2. Dasatinib
Dasatinib is a second-generation TKI with dual Src and Abl kinase inhibition activity [126, 
127]. It is active against all imatinib-resistant kinase domain mutations apart from T315I 
mutation, thus having superior potency for inhibiting bcr-abl fusion protein compared to 
imatinib [126, 127]. The use of dasatinib is associated with the following adverse effects: bone 
marrow suppression, fluid retention, pleural effusion, skin eruptions, cardiac conduction 
disturbances, and colitis that may be hemorrhagic, immune-mediated, or cytomegalovirus-
induced [127].
Dasatinib is usually used in combination with cytotoxic chemotherapy such as hyper-CVAD 
regimen to control Ph+ ALL prior to allogeneic HSCT [126]. It can also be used in the setting 
of post-HSCT as maintenance therapy to prevent disease relapse or to eliminate MRD [127]. In 
older adults who are not candidates for allogeneic HSCT or younger patients who are unable 
to tolerate intensive chemotherapy, an induction regimen composed of targeted therapies 
such as dasatinib and corticosteroids may offer the potential of greater and longer responses, 
thus avoiding the morbidity associated with the use of cytotoxic chemotherapy [128, 129]. In 
this combination, dasatinib inhibits Scr-Abl kinase while corticosteroids modulate Bcl2 fam-
ily of proteins leading to apoptosis [128]. The combination of dasatinib and corticosteroids 
is associated with relapses mainly due to T315I mutations that can be further treated with 
ponatinib [129].
3.1.3. Nilotinib
The use of TKIs, including the second-generation drugs such as nilotinib, in the post-HSCT 
setting in patients with Ph+ ALL could potentially reduce relapse rates [130, 131]. Studies 
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on the use of nilotinib have shown the following results: (1) safety and efficacy of nilotinib 
prophylaxis to prevent relapse of Ph+ ALL after allogeneic HSCT, (2) effectiveness of nilo-
tinib to control MRD and to convert patients to CMR, and (3) achievement of prolongation of 
survival without jeopardizing immune function or reconstitution following HSCT [130–133]. 
However, side effects such as prolongation of QT interval on electrocardiogram and early 
disease relapse post-HSCT may limit its use [132, 134].
3.1.4. Ponatinib
Ponatinib is a pan-bcr/abl TKI which is capable of inhibiting T315I kinase domain mutation 
that confers resistance to other TKIs and dismal prognosis [95, 129]. Ponatinib can be given 
prior to HSCT as bridging therapy to control disease and to prevent disease relapse following 
HSCT [95, 135]. Rapid hematological responses can be obtained in almost all patients but mor-
phologic and molecular responses can unfortunately be short-lived [95]. One study showed 
that patients with Ph+ ALL who underwent allogeneic HSCT had better survival than those 
who received ponatinib alone [136].
3.2. Nelarabine
Nelarabine is a purine nucleoside analogue and a soluble prodrug of Ara-G with specific cyto-
toxicity against T-lymphocytes [136–145]. It has significant activity in patients with T-cell ALL 
and T-cell lymphoblastic lymphoma (LBL) [137, 140, 142, 143, 146]. In October 2005, nelara-
bine gained an accelerated approval by the food and drug authority (FDA) in the USA for the 
treatment of children and adults with T-cell ALL and T-cell LBL who are in relapse or refrac-
tory to at least two chemotherapeutic regimens [137–145]. It has been used as a single agent 
or in combination with intensive chemotherapy or P13K inhibitors [138, 142, 143, 146–148]. 
The use of nelarabine in the treatment of patients having T-cell ALL relapsing after alloge-
neic HSCT has been associated with 90% OS at 1 year [144]. The adverse effects of nelarabine 
include: (1) myelosuppression with neutropenia and thrombocytopenia and (2) neurotoxic-
ity, which is the commonest side effect, may be transient and reversible and can manifest as 
depression in the level of consciousness, sensory and motor neuropathies, and Guillain-Barre 
syndrome [139–145]. The mechanisms of resistance to nelarabine include: (1) reduced drug 
incorporation into DNA and (2) anti-apoptosis [149]. Other novel purine analogues, such as 
clofarabine and forodesine, have demonstrated significant anti-tumor activity in relapsed/
refractory T-cell ALL and T-cell LBL [138].
3.3. Blinatumomab
Blinatumomab is a bispecific T-cell engager monoclonal antibody construct that is designed 
to direct cytotoxic T-cells to CD19-expressing B-cells [150, 151]. It is indicated (1) in the 
treatment of Ph− relapsed/refractory pre-B ALL, (2) to induce GVL reaction in patients with 
pre-B ALL relapsing post-allogeneic HSCT, and (3) in the treatment of HR patients with Ph+ 
ALL [150, 151]. In a phase II single arm multicenter study that included 45 patients with 
HR-Ph+ ALL patients who had relapsed or were refractory to TKIs, single agent blinatu-
momab showed remarkable anti-leukemic activity as 88% of patients achieved CR or CR 
with partial hematologic recovery and a median OS of 7.1 months [151]. The adverse effects 
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of blinatumomab include: fever, febrile neutropenia, headache, neurotoxicity, such as apha-
sia, and cytokine release syndrome (CRS) [140].
3.4. CAR T-cells
Chimeric antigen receptors (CAR) consist of an extracellular antigen recognition domain linked 
to an intracellular signaling domain [152, 153]. An important part of CAR design in choosing 
an optimal tumor-associated antigen to target [152]. A patient’s own T-cells may be geneti-
cally modified to express an artificial T-cell receptor termed CAR designed to be specific to a 
tumor-associated antigen [154]. CARs are artificial receptors that redirect antigen specificity, 
activate T-cells, and further enhance T-cell function through their costimulatory component 
[155]. Ideally, the target antigen should only be expressed on tumor cells and not on normal 
cells in order to ensure that there is no (on-target-off tumor) activity that could result in tox-
icity [152]. The most extensively investigated CAR in clinical setting targets CD19, which is 
expressed not only in most B-cell malignancies but also in normal B-cells. Thus, CAR-mediated 
tumor destruction is accompanied by CAR-mediated destruction of normal B-cells resulting in 
B-cell aplasia [152].
Center Patients 
(number 
and 
diagnosis)
Viral transduction Conditioning therapy Cytokine 
release 
syndrome 
(%)
Outcome
Memorial 
Sloan Kettering 
Cancer Center
27
Relapsed 
B-ALL
Retroviral 
transduction
Cyclophosphamide 18 • 88% CR
• Molecular CR: 70%
University of 
Pennsylvania 
and Children 
Hospital of 
Philadelphia
25
Pediatric 
R/R 
B-ALL
Lentiviral 
transduction
No conditioning 
therapy
27 • 90% morphologic 
remission
• 73% MRD by flow 
cytometry
• 6 patients relapsed
Fred 
Hutchinson 
Cancer 
Research 
Center
9
Phase I
Lentiviral 
transduction
Cyclophosphamide 33.3 • 7 patients had CR with 5 
having MRD
MD Anderson 
Cancer Center
10
CAR 
T-cells 
infused 
following 
allogeneic 
HSCT
Sleeping beauty 
transposon 
electroporation
No conditioning 
therapy
30 • 10 patients achieved CR 
at 5 months
ALL, acute lymphoblastic leukemia; R/R, relapsed/refractory; CR, complete remission; HSCT, hematopoietic stem cell 
transplantation; CAR, chimeric receptor antigen; and MRD, minimal residual disease.
Table 4. Clinical trials on the use of CAR-T cells in ALL patients.
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CAR T-cell therapy involves several laboratory, technical, and clinical procedures that include: 
(1) obtaining peripheral blood mononuclear cells by leukapheresis, (2) CD3 (T-cell) separation, 
(3) engineering of T-cells to express CAR by gene transfer technology, viral transduction, or 
1. Monoclonal antibodies, immunotoxins, and immunoconjugate antibodies:
• CD20:
 ○ Rituximab
 ○ Obinutuzumab
 ○ Ofatumumab
 ○ REGN 1979
• CD 22:
 ○ Epratuzumab
 ○ Inotuzumab ozogamicin (IO)
 ○ Moxetumomab pasudotox, reformulation of BL22
• CD 19:
a. Single CD 19 monoclonal antibodies:
 ○ Coltuximab ravtansine [SAR3419]
 ○ Denintuzumab mafodotin [SGN-CD19A]
 ○ ADC-402, newest CD19 monoclonal antibody
b. Dual monoclonal antibodies including anti-CD19 activity:
 ○ Combotox: Anti-CD19 and anti- CD22
 ○ Bispecific T cell engager (BITE) construct: Blinatumomab [anti-CD3; CD 19 construct]
2. Proteasome inhibitors: Bortezomib
3. JAK inhibitors: Ruxolitinib
4. Hypomethylating agents: Decitabine
5. P13K- mTOR inhibitors:
• NVP-BEZ 235
• NCT01756118
• NCT 02484430
• NCT 01523977
• NCT 01403415
• NCT 01614197
• NCT 01184885
6. Chimeric antigen receptor T-cells (CAR T-cells)
Table 5. Novel and targeted therapies in acute lymphoblastic leukemia.
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genetic modification with CD19-specific CAR to target tumor in addition to cell expansion, (4) 
lymphodepletion by administration of pre-infusion conditioning therapy in the form cyclo-
phosphamide or cyclophosphamide and fludarabine, (5) CAR T-cell infusion to target CD 19+ 
B-cells, and (6) cell death or apoptosis of CD19+ lymphoblasts [152–154, 156]. Indication for 
CAR T-cell therapy include: (1) relapsed and refractory B-cell ALL, (2) chronic lymphocytic 
leukemia, (3) acute myeloid leukemia, (4) follicular lymphoma, (5) diffuse large B-cell lym-
phoma, (6) multiple myeloma, (7) Waldenstrom’s macroglobulinemia, and (8) treatment of 
relapse post-allogeneic HSCT for B-cell malignancies [152, 157, 158]. Studies have shown that 
treatment options in relapse after allogeneic HSCT for lymphoid malignancies including ALL 
include: (1) DLI, (2) salvage chemotherapy followed by a second allogeneic HSCT, and (3) 
CAR T-cell infusions, a cell-based immunotherapy that can effectively enhance and maintain 
antitumor GVL response after transfusion into patients [152, 157, 158].
Adverse effects or complications of CAR T-cell therapy in relapsed and refractory ALL include: 
(1) CRS, which can be severe and life-threatening, may manifest with: hyperpyrexia, hypoten-
sion, capillary leak syndrome, neurological manifestations, myalgia, and respiratory as well 
as renal insufficiency, (2) neurotoxicity in the form of delirium and seizures, (3) macrophage 
activation syndrome, (4) aplasia of normal B-lymphocytes, and (5) death that may occasion-
ally be encountered [155, 159–165]. Serum biochemical markers of CRS following CAR T-cell 
therapy in relapsed and refractory ALL include C-reactive protein and ferritin [155, 159, 165]. 
Management of CRS includes: supportive care, corticosteroids, vasopressors, ventilatory sup-
port, and anti-interleukin-6 receptor antibody (tocilizumab) therapy [165]. The main clinical 
trials on the use of CAR T-cells are shown in Table 4 [152, 156]. Novel and targeted therapies 
that can be used in the treatment of patients with ALL are shown in Table 5 [1–3, 56, 160, 161].
4. Future directions
Recently, management of patients with ALL has improved dramatically due to several rea-
sons such as improvements in our understanding of the disease biology; improvements in 
the diagnostic techniques, including molecular genetics, that help in disease stratification; 
improvements in supportive care; adoption of dose-intense pediatric-inspired chemothera-
peutic regimens in AYAs; progress in HSCT including donor selection, conditioning therapies, 
and prevention as well as treatment of GVHD; monitoring of MRD; and the availability of 
several novel agents and targeted therapies in addition to cellular and immunotherapies. The 
availability of the modern therapeutic interventions has translated into improved response 
rates and outcomes including OS. The integration of various novel and targeted therapies 
before and after transplantation has further improved the outcomes of patients with ALL.
Different therapeutic interventions available for treating children and adults with ALL should 
be considered complementary to each other. Future studies should focus on the optimal inte-
gration of these novel therapies into the treatment paradigm of this malignancy in order to 
achieve higher rates of response, disease control as well as long-term survival. Risk stratifica-
tion of ALL will help in tailoring the management of patients according to their risk category 
taking into consideration their clinical manifestations, laboratory findings, including cytoge-
netic and molecular profiles, as well as responses to therapeutic interventions.
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In children with ALL, the role of HSCT has decreased due to the use of intensified chemo-
therapeutic regimens and the incorporation of novel and targeted therapies into the upfront 
treatment. However, patients with HR features, those with MRD, and patients with relapsed 
or refractory disease should be considered for HSCT and novel therapies should be adminis-
tered whenever indicated.
5. Conclusion
Intensified pediatric chemotherapeutic regimens show poor outcome of ALL in adults com-
pared to children particularly in patients with HR features or disease relapse. Thus, alloge-
neic HSCT has more indications in adults than in children. However, the integration of other 
therapeutic interventions into the management of ALL, before and after transplantation, is 
likely to improve the outcome of patients further.
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